Results 221 to 230 of about 22,035 (254)

Darunavir/ritonavir

Reactions Weekly, 2013
openaire   +2 more sources

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Lancet, The, 2014
Bonaventura Clotet, Judith Feinberg, Andrea Antinori   +2 more
exaly  

Darunavir

2013
openaire   +1 more source

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

The Lancet HIV, 2018
J. Molina, K. Squires, P. Sax, P. Cahn, J. Lombaard, E. Dejesus, M. Lai, Xia Xu, A. Rodgers, L. Lupinacci, Sushma Kumar, P. Sklar, B. Nguyen, G. Hanna, C. Hwang   +14 more
semanticscholar   +1 more source

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

Bioorganic and Medicinal Chemistry, 2007
Arun K Ghosh
exaly  

Darunavir/raltegravir

Reactions Weekly, 2018
openaire   +1 more source

Cobicistat/darunavir

Reactions Weekly, 2017
openaire   +1 more source

Cotrimoxazole/darunavir

Reactions Weekly, 2021
openaire   +1 more source

Darunavir

Drugs, 2012
exaly   +2 more sources

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

Lancet, The, 2014
Laura Richert, Elizabeth C George, Andrea Antinori   +2 more
exaly